Chief scientific officer

Facilitating Investment Decisions for Small to Midsize Pharmaceutical and Biotechnology Companies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 13, 2023
EST, Doctor of Philosophy, Chief scientific officer, MD, Pharmaceutical industry

TORONTO, Nov. 13, 2023 /PRNewswire-PRWeb/ -- This webinar discusses the strategic contributions of a contract research organization as a partner to support the clinical development process.

Key Points: 
  • TORONTO, Nov. 13, 2023 /PRNewswire-PRWeb/ -- This webinar discusses the strategic contributions of a contract research organization as a partner to support the clinical development process.
  • Strategic and transactional relationships extending through discovery and development help facilitate the development and commercial success of advanced technologies, targeting increasingly nuanced patient populations.
  • Between the concept of a novel chemical, biological, or advanced therapeutic medicinal product and the commercial debut of a therapeutic entity fall innumerable business decisions.
  • Join this webinar to explore the critical role of contract research organizations in supporting the clinical development process and the strategic decisions that shape the journey from concept to commercialization in the pharmaceutical industry.

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, November 7, 2023
Temporal lobe epilepsy, FDA, CSL, Research, Sale, IND, SOD1, Food, Chief scientific officer, ALS, Fabry disease, Workforce, Acquisition, Phase, Neuroscience, Hand, Nobel Prize, Safety, ARD International Music Competition, Investment, France, Patient, Immunosuppression, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Management, Cryptocurrency, EU

and AMSTERDAM, Nov. 07, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2023 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, Nov. 07, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2023 and highlighted recent progress across its business.
  • Screening and patient enrollment is expected to begin in the fourth quarter of 2023 with first patient dosing planned to occur in the first quarter of 2024.
  • The Company expects to initiate patient screening in the fourth quarter of 2023 with first patient dosing planned to occur in the first quarter of 2024.
  • AMT-191 for the treatment of Fabry disease – The Company expects to submit an IND in the fourth quarter of 2023 and to begin patient dosing in 2024.

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Retrieved on: 
Tuesday, October 24, 2023
Alzheimer's disease, AAV, Control, SR, Chief scientific officer, Seed, Research, Poster, Cell, Science, Gene, APOE, Annual general meeting, ESGCT, Chemistry, European Society of Gene and Cell Therapy, GRIK2, Patient, Temporal lobe epilepsy, Pharmaceutical industry, Management, Tutoring

LEXINGTON, Mass.

Key Points: 
  • LEXINGTON, Mass.
  • and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting being held October 24-27 in Brussels, Belgium.
  • “Our multiple presentations at ESGCT demonstrate uniQure’s continued leadership in advancing important research within the field of gene therapy, as well as highlight our industry-leading expertise in AAV gene therapy manufacturing,” stated Richard Porter, Ph.D., Chief Business and Scientific Officer at uniQure .
  • “We look forward to sharing these presentations that feature our technology and platform experience across numerous programs.”
    Specific details on uniQure’s presentations taking place at ESGCT include:
    Presenter: Richard Porter, Chief Business and Scientific Officer, uniQure
    Session Title and Location: CNS & sensory diseases II, Session 10a, Shed 2A
    Session Title and Location: CNS & sensory diseases I, Session 2c, Maison de la Poste
    Title: Pivotal safety studies for AMT-260, a novel AAV9-dual microRNA-based vector targeting GRIK2 for the treatment of temporal lobe epilepsy (Poster #433)
    Presenter: Nick Pearson, Sr. Director Toxicology & Translational Safety, Non-Clinical, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 – 21:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 18:15 – 19:30, Thursday October 26, 19:30 – 20:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 – 21:30 GMT+2
    Title: Silence and replace as potential treatment for Alzheimer Disease: in concert lowering toxic APOE and augmenting protective APOE (Poster #049)
    Poster Session Date and Time: Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 – 21:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 18:15-19:30, Thursday, October 26, 19:30-20:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 18:15-19:30, Thursday, October 26, 19:30-20:30 GMT+2
    Presenter: Erich Ehlert, Director – Process Development – Chemistry, Manufacturing and Controls, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00-18:15, Thursday, October 26, 20:30-21:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 17:00-18:15, Thursday, October 26, 20:30-21:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 18:15-19:30, Thursday, October 26, 19:30-20:30 GMT+2
    Presenter: Zandra Félix Garza, Project Manager- BPU – Cells, Seeds and Research Supply, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00-18:15, Thursday, October 26, 20:30-21:30 GMT+2

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

Retrieved on: 
Thursday, October 5, 2023
Neuroscience, ALS, Acquisition, Temporal lobe epilepsy, CSL Behring, CSL, Chief scientific officer, Risk, Fabry disease, IND, Patient, FDA, GMP, Alzheimer's disease, Workforce, Phase, AAV, Rich Porter, MA, CNS, Research, Genetic distance, Construction, Management, Pharmaceutical industry, Fabry

LEXINGTON, Mass. and AMSTERDAM, Oct. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a strategic reorganization that will significantly reduce operating expenses while supporting focused execution to rapidly advance multiple clinical-stage programs to proof-of-concept.

Key Points: 
  • and AMSTERDAM, Oct. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a strategic reorganization that will significantly reduce operating expenses while supporting focused execution to rapidly advance multiple clinical-stage programs to proof-of-concept.
  • “At uniQure, our highest priority is to deliver innovative, life-changing therapies to patients with significant unmet needs.
  • To accomplish our mission and generate near-term value for our stakeholders, we will implement a strategic restructuring of our business,” stated Matt Kapusta, chief executive officer of uniQure .
  • “We are taking important actions today to cut operating expenses while ensuring that we have the necessary resources to advance our prioritized clinical-stage programs as rapidly as possible to proof-of-concept.

Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

Retrieved on: 
Wednesday, July 26, 2023
PALM, Insurance, Pharmacovigilance, DRS, Psychedelic drug, ASIB, Anorexia nervosa, Incidence, Patient, Panic disorder, News, NYSE, GAD, Opioid, University, FNM, Research, DSM-IV codes, Designated activity company, TSX, Growth, Security (finance), Rare, FDA, Mental health, Safety, Worldwide, NOT, Depression, Medicine, LSD, MDD, CMPS, Therapy, NEO, MindMed, Major depressive disorder, Chief scientific officer, Partnership, Nature Medicine, Anxiety, Quality of life, Form 10-K, Plant, NEVER, MAPS, ANY, OTCQX, Annual report, Pharmaceutical industry, Nursing, Behavior

PALM BEACH, Fla., July 26, 2023 /PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise in the coming years.  Psychedelic medicines are a group of substances, including chemicals, such as LSD, and plants used to treat multiple mental disorders, including resistant depression, opiate addiction, and panic disorder, among others. This medicine changes and enhances sensory perceptions, thought processes, and energy levels and facilitates favorable experiences.  A recent report from Insight Ace Analytic projected that the Psychedelic Therapeutics Market Size is valued at 3.94 Billion in 2022 and is predicted to reach 13.29 Billion by the year 2031 at a 14.92 % CAGR during the forecast period for 2023-2031.  The report said: "The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world. Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market. In addition, the market is anticipated to expand lucratively as a result of the growing need for medicines to treat psychological drug dependency. On the other hand, a greater acceptance of non-therapeutic treatments over allopathic therapies and tight rules implemented by various governments to commercialize psychedelic medications may inhibit the market growth."  Active Companies active today in markets include:  Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Numinus Wellness Inc. (OTCQX: NUMIF) (TSX: NUMI).

Key Points: 
  • A recent report from Insight Ace Analytic projected that the Psychedelic Therapeutics Market Size is valued at 3.94 Billion in 2022 and is predicted to reach 13.29 Billion by the year 2031 at a 14.92 % CAGR during the forecast period for 2023-2031.
  • The report said: "The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world.
  • Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market.
  • Worldwide has a track record of successful patient recruitment for psychedelic trials and global relationships with best-in-class investigative sites.

Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

Retrieved on: 
Wednesday, July 26, 2023
PALM, Insurance, Pharmacovigilance, DRS, Psychedelic drug, ASIB, Anorexia nervosa, Incidence, Patient, Panic disorder, News, NYSE, GAD, Opioid, University, FNM, Research, DSM-IV codes, Designated activity company, TSX, Growth, Security (finance), Rare, FDA, Mental health, Safety, Worldwide, NOT, Depression, Medicine, LSD, MDD, CMPS, Therapy, NEO, MindMed, Major depressive disorder, Chief scientific officer, Partnership, Nature Medicine, Anxiety, Quality of life, Form 10-K, Plant, NEVER, MAPS, ANY, OTCQX, Annual report, Pharmaceutical industry, Nursing, Behavior

PALM BEACH, Fla., July 26, 2023 /PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise in the coming years.  Psychedelic medicines are a group of substances, including chemicals, such as LSD, and plants used to treat multiple mental disorders, including resistant depression, opiate addiction, and panic disorder, among others. This medicine changes and enhances sensory perceptions, thought processes, and energy levels and facilitates favorable experiences.  A recent report from Insight Ace Analytic projected that the Psychedelic Therapeutics Market Size is valued at 3.94 Billion in 2022 and is predicted to reach 13.29 Billion by the year 2031 at a 14.92 % CAGR during the forecast period for 2023-2031.  The report said: "The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world. Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market. In addition, the market is anticipated to expand lucratively as a result of the growing need for medicines to treat psychological drug dependency. On the other hand, a greater acceptance of non-therapeutic treatments over allopathic therapies and tight rules implemented by various governments to commercialize psychedelic medications may inhibit the market growth."  Active Companies active today in markets include:  Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Numinus Wellness Inc. (OTCQX: NUMIF) (TSX: NUMI).

Key Points: 
  • A recent report from Insight Ace Analytic projected that the Psychedelic Therapeutics Market Size is valued at 3.94 Billion in 2022 and is predicted to reach 13.29 Billion by the year 2031 at a 14.92 % CAGR during the forecast period for 2023-2031.
  • The report said: "The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world.
  • Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market.
  • Worldwide has a track record of successful patient recruitment for psychedelic trials and global relationships with best-in-class investigative sites.

TATAA Biocenter promotes Sofia Adolfsson to Scientific Officer and Head of Bioinformatics

Retrieved on: 
Tuesday, July 25, 2023
Chief scientific officer, Lund University, Karolinska Institute, TATAA, Head, ETH Zurich, Research, Doctor of Philosophy, Uppsala University, Medicine, Growth, Management, Bioinformatics

GOTHENBURG, Sweden, July 25, 2023 /PRNewswire/ -- TATAA Biocenter AB (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the promotion of Sofia Adolfsson to Head of Bioinformatics and Scientific Officer.

Key Points: 
  • GOTHENBURG, Sweden, July 25, 2023 /PRNewswire/ -- TATAA Biocenter AB (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the promotion of Sofia Adolfsson to Head of Bioinformatics and Scientific Officer.
  • In her new role, Sofia will support the Company's leadership team in its continued growth and long-term ambitions.
  • Sofia previously held roles at the Uppsala University, the Karolinska Institutet, and Lund University before joining TATAA Biocenter in 2021 as Head of Bioinformatics.
  • "Sofia has been an invaluable member of our team since she joined us in 2021," said Mathias Hallin, CEO of TATAA Biocenter.

TATAA Biocenter promotes Sofia Adolfsson to Scientific Officer and Head of Bioinformatics

Retrieved on: 
Tuesday, July 25, 2023
Chief scientific officer, Lund University, Karolinska Institute, TATAA, Head, ETH Zurich, Research, Doctor of Philosophy, Uppsala University, Medicine, Growth, Management, Bioinformatics

GOTHENBURG, Sweden, July 25, 2023 /PRNewswire/ -- TATAA Biocenter AB (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the promotion of Sofia Adolfsson to Head of Bioinformatics and Scientific Officer.

Key Points: 
  • GOTHENBURG, Sweden, July 25, 2023 /PRNewswire/ -- TATAA Biocenter AB (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the promotion of Sofia Adolfsson to Head of Bioinformatics and Scientific Officer.
  • In her new role, Sofia will support the Company's leadership team in its continued growth and long-term ambitions.
  • Sofia previously held roles at the Uppsala University, the Karolinska Institutet, and Lund University before joining TATAA Biocenter in 2021 as Head of Bioinformatics.
  • "Sofia has been an invaluable member of our team since she joined us in 2021," said Mathias Hallin, CEO of TATAA Biocenter.

OPEN Health announces a new team of experts will lead its HEOR & Market Access Scientific Office

Retrieved on: 
Monday, July 24, 2023
Meta-analysis, Chief scientific officer, The New England Journal of Medicine, Partnership, Data analysis, Health, OPEN, Research, Hout, CEAC, Science, Acquisition, Publication, Master of Science, Patient-centered outcomes, Management

London, UK, July 24, 2023 (GLOBE NEWSWIRE) -- OPEN Health, a global provider of consultancy , HEOR and market access , and scientific communications services, today announced a new team of experts will lead its HEOR & Market Access Scientific Office.

Key Points: 
  • London, UK, July 24, 2023 (GLOBE NEWSWIRE) -- OPEN Health, a global provider of consultancy , HEOR and market access , and scientific communications services, today announced a new team of experts will lead its HEOR & Market Access Scientific Office.
  • Our scientific experts are here to support the HEOR and market access team with their amazing research developing innovative solutions.” Elisabeth commented.
  • The Scientific Office is made up of experts who bring unique skillsets from across OPEN Health’s HEOR & market access service areas.
  • Craig Bennison, MSc, Executive Director and Global Innovation Lead for OPEN Health HEOR & Market Access, will also join the team and will focus specifically on innovation.

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

Retrieved on: 
Tuesday, May 30, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Chief scientific officer, Collateral circulation, DMAC, University, Senior, Internal medicine, Patient-Centered Outcomes Research Institute, Harvard T.H. Chan School of Public Health, Stroke, TPA, Harvard University, Associate, Bangladesh Technical Education Board, Harvard Medical School, NYSE, Master of Science, Public health, Miami University, Publication, National academy, Beth Israel Hospital, Patient, Division, Neuromodulation, PCORI, Executive Committee, Case Western Reserve University School of Medicine, S-1 Executive Committee, Biostatistics, HEAL, Neurology, NIH, Interventional cardiology, Pharmaceutical industry, Nursing, Science, Medtronic, Brigham, Parkland Memorial Hospital, Medicine

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.
  • Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee.
  • Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009.
  • Before joining Medtronic, he was the founder and Chief Scientific Officer of the Harvard Clinical Research Institute in Boston.